

SPECIMEN

Your No: WS05-xxxx **Case No:** C05-00xxx **Req. No:** Txxxxx
Collected: 06-08-05, PM **Sent:** 06-09-05, PM **Received:** 06-09-05, PM
Preliminary: 06-10-05, PM **Final:** 06-14-05, AM **Addendum:** None

PATIENT

Name: HIPAA, Compliant
DOB: 03-25-1945 (60 yr) **Sex:** M
ID#: xxx-xx-0000 **Tel:** xxx-xxx-xxxx

PHYSICIAN

Facility: St. Elsewhere Hospital **Account No:** 12345-2
Pathologist: John Doe, MD **Tel:** xxx-xxx-xxxx **Fax:** xxx-xxx-xxxx
Attending: John Doe, MD

Diagnosis Category: Neoplastic
 Benign Changes
 Normal

Notification Status: Immediate
 Next Day
 Routine


Report Status: Preliminary
 Final
 Addendum

IMMUNOHISTOCHEMISTRY DIAGNOSIS


Duodenum - Biopsy: Early MALT Lymphoma, See Comment.

Electronically Signed By: Sherif A. Nasr, MD, **Tel:** 888.599.LABS (5227) **Mobile:** 732.236.5950


A copy of this report can be viewed at siParadigm.com under requisition number Txxxx and case number C05-00xxx.



BCL-2(+)



H&E (400X)



CD23+

COMMENTS

There is a prominent follicle with a benign germinal center and expanded marginal zone by centrocytoid cells with monocytoid features. The immunostains (CD23 and BCL-6) show evidence of follicular colonization. Overall the features are those of early MALT lymphoma. B-cell gene rearrangement studies can be performed for further confirmation, if clinically pertinent.

MALT lymphomas of the duodenum are uncommon and have been reported with and without associated gastric *H. pylori* infection. Early MALT lymphomas of the stomach are known to regress after successful treatment of *H. pylori* infection. Clinical correlation and follow-up is appreciated.

RESULTS

Antibody

Specificity

Cells of Interest

BCL-1	Mantle Cell Lymphoma (0% of MALTOMAs)	Negative
BCL-2	Follicular Lymphoma (79% of MALTOMAs)	Positive
BCL-6	Follicular Center Cells (0% of MALTOMAs)	Negative (see comment)
CD3	Mature T-cells	Negative
CD5	Pan T-cells & CLL/MCL (0% of MALTOMAs)	Negative

CD10	Follicular Center Cells (0% of MALTOMAs)	Negative
CD20	Pan B-cells	Positive
CD23	CLL (2% of MALTOMAs)	Negative (see comment)
CD43	Non-B leukocytes (37% of MALTOMAs)	Negative
Kappa	~ 60% of Plasma Cells	Polyclonal
Lambda	~ 40% of Plasma Cells	Polyclonal
PCK (AE1/AE3)	Pancytokeratin	No lymphoepithelial lesions

SPECIMEN INFORMATION

Received: 1 paraffin block and 1 slide labeled S05-3362-I
Returned: 1 paraffin block and 14 slides (2 H&E and 12 IHC).

The reagents used for these assays are analyte specific reagents (ASR). Their performance characteristics have been validated by siParadigm diagnostic informatics, LLC, Oradell, NJ. They have not been reviewed by the FDA. The FDA has deemed that such approval is unwarranted. These assays are for clinical use and should not be viewed as experimental or for "research use only".

End of report.